Abstract:Background: Medulloblastoma is the most common malignant brain tumor in children accounting for about 10% of all pediatric cancer deaths. According to the 2016 WHO Classification, four molecular subtypes of medulloblastoma including WNT, SHH, Group 3 and Group 4 were characterized by high-throughput gene expression profiling. These molecular subtypes display distinct clinical, demographic and genetic features that are associated with prognostic and therapeutic differences. Because it is currently impractical to perform microarray analysis in clinical settings, distinguishing the four molecular subgroups of medulloblastoma in the daily treatment of patients, as well in the setting of clinical trials, remains an important challenge. Methods: Three medulloblastoma microarray datasets were curated to perform an integrative analysis. To identify a reliable biomarker, a training-validating approach was adopted in this study. The gene expression profiles of 103 samples were selected as a training set for signature identification. Additional 358 samples were used for signature validation. The Gene Ontology and KEGG pathway analysis were performed to reveal the biological features of candidate genes. Results: A 23-gene expression signature derived from the training set was strongly associated with the molecular subtypes of medulloblastoma. The 23-gene expression signature was validated in 8 WNT, 61 SHH, 62 Group 3 and 227 Group 4 samples. With the 23-gene expression signature, 8 samples were classified as WNT, 63 as SHH, 73 as Group 3 and 214 as Group 4. The gene expression-based assignments reached a 95.5% overall agreement with the reference diagnoses (342 of 358; 95% CI: 0.928 to 0.974). Sensitivity ranged from 94% to 100%, while specificity ranged from 96% to 100%. The functional enrichment analysis showed that 23 genes were significantly associated with signal transduction and WNT signaling pathway. Conclusions: A 23-gene expression signature that could accurately discriminate molecular subtypes of medulloblastoma was identified in this study. Our results may prompt further development of this gene expression signature into a molecular assay amenable to routine clinical practice. Legal entity responsible for the study: Qinghua Xu. Funding: Has not received any funding. Disclosure: J. Chen, C. Chen, Y. Sun, L. Chen: Employment: Canhelp Genomics Co. Ltd. Q. Xu: Employment, stock ownership: Canhelp Genomics Co. Ltd. All other authors have declared no conflicts of interest.

PATH-13. SNCA, A NOVEL MARKER FOR GROUP 4 MEDULLOBLASTOMAS

SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis.

PDTB-08. Mir-449a, A POTENTIAL DIAGNOSTIC BIOMARKER FOR WNT GROUP OF MEDULLOBLASTOMA

Identification and Validation of SNHG Gene Signature to Predict Malignant Behaviors and Therapeutic Responses in Glioblastoma

Single‐Cell Chromatin Accessibility Analysis Reveals Subgroup‐Specific TF‐NTR Regulatory Circuits in Medulloblastoma

Medulloblastoma: Molecular understanding, treatment evolution, and new developments

Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment

Accuracy analysis of identifying molecular subtypes of children and adolescents with medulloblastoma using real-time fluorescence quantitative PCR

[Mir-449A is a Potential Epigenetic Biomarker for WNT Subtype of Medulloblastoma].

Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas

Identification and Validation of a 23-Gene Expression Signature for Subtype Classification of Medulloblastoma.

MEDU-02. DIFFERENTIAL EXPRESSION OF FOLATE RECEPTOR 1 IN MEDULLOBLASTOMA AND ITS RELATIONSHIP TO CLINICOPATHOLOGICAL CHARACTERISTICS AND TARGETED THERAPY

Distinctive Localization and MRI Features Correlate of Molecular Subgroups in Adult Medulloblastoma

Molecular Subgroups of Adult Medulloblastoma: a Long-Term Single-Institution Study.

Comprehensive analysis and validation reveal potential MYCN regulatory biomarkers associated with neuroblastoma prognosis

Abstract 3877: Multi-modal analysis of paracrine signaling in group 3/4 medulloblastoma

A CTNNB1-altered Medulloblastoma Shows the Immunophenotypic, DNA Methylation and Transcriptomic Profiles of SHH-activated, and Not WNT-activated, Medulloblastoma.

PDTM-37. THE ROLE OF EXOSOME Mirna DURING THE PROGRESSION OF MEDULLOBLASTOMA

A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience.

Metabolomic profiling of childhood medulloblastoma: contributions and relevance to diagnosis and molecular subtyping

Development and validation of a 23-gene expression signature for molecular subtyping of medulloblastoma in a long-term Chinese cohort